The next firms are anticipated to report earnings after hours on 03/23/2023. Go to our Earnings Calendar for a full checklist of anticipated earnings releases.
Oxford Industries, Inc. (OXM)is reporting for the quarter ending January 31, 2023. The textile firm’s consensus earnings per share forecast from the three analysts that comply with the inventory is $2.14. This worth represents a 27.38% improve in comparison with the identical quarter final yr. Up to now yr OXM has beat the expectations each quarter. The best one was within the 4th calendar quarter the place they beat the consensus by 21.67%. Zacks Funding Analysis experiences that the 2023 Value to Earnings ratio for OXM is 10.93 vs. an trade ratio of 19.40.
ADMA Biologics Inc (ADMA)is reporting for the quarter ending December 31, 2022. The biomedical (gene) firm’s consensus earnings per share forecast from the two analysts that comply with the inventory is $-0.06. This worth represents a 33.33% improve in comparison with the identical quarter final yr. ADMA missed the consensus earnings per share within the 1st calendar quarter of 2022 by -25%. Zacks Funding Analysis experiences that the 2022 Value to Earnings ratio for ADMA is -10.03 vs. an trade ratio of three.00.
Harrow Well being, Inc. (HROW)is reporting for the quarter ending December 31, 2022. The medical companies firm’s consensus earnings per share forecast from the 1 analyst that follows the inventory is $-0.15. This worth represents a 1400.00% lower in comparison with the identical quarter final yr. Zacks Funding Analysis experiences that the 2022 Value to Earnings ratio for HROW is -26.17 vs. an trade ratio of 8.10.
Alpine Immune Sciences, Inc. (ALPN)is reporting for the quarter ending December 31, 2022. The drug firm’s consensus earnings per share forecast from the two analysts that comply with the inventory is $-0.36. This worth represents a 30.77% improve in comparison with the identical quarter final yr. The “days to cowl” for this inventory exceeds 11 days. Zacks Funding Analysis experiences that the 2022 Value to Earnings ratio for ALPN is -3.97 vs. an trade ratio of -0.80.
Torrid Holdings Inc. (CURV)is reporting for the quarter ending January 31, 2023. The retail (shoe) firm’s consensus earnings per share forecast from the 6 analysts that comply with the inventory is $-0.07. This worth represents a 177.78% lower in comparison with the identical quarter final yr. The final two quarters CURV had adverse earnings surprises; the newest report they missed by -36.36%. Zacks Funding Analysis experiences that the 2023 Value to Earnings ratio for CURV is 5.11 vs. an trade ratio of 17.70.
Heron Therapeutics, Inc. (HRTX)is reporting for the quarter ending December 31, 2022. The drug firm’s consensus earnings per share forecast from the two analysts that comply with the inventory is $-0.25. This worth represents a 53.70% improve in comparison with the identical quarter final yr. The “days to cowl” for this inventory exceeds 14 days. Zacks Funding Analysis experiences that the 2022 Value to Earnings ratio for HRTX is -1.08 vs. an trade ratio of -0.80.
Celcuity Inc. (CELC)is reporting for the quarter ending December 31, 2022. The biomedical (gene) firm’s consensus earnings per share forecast from the two analysts that comply with the inventory is $-0.54. This worth represents a 20.00% lower in comparison with the identical quarter final yr. Zacks Funding Analysis experiences that the 2022 Value to Earnings ratio for CELC is -5.11 vs. an trade ratio of three.00.
Quest Useful resource Holding Company (QRHC)is reporting for the quarter ending December 31, 2022. The waste elimination firm’s consensus earnings per share forecast from the 1 analyst that follows the inventory is $0.07. This worth represents a 12.50% lower in comparison with the identical quarter final yr. QRHC missed the consensus earnings per share within the third calendar quarter of 2022 by -60%. Zacks Funding Analysis experiences that the 2022 Value to Earnings ratio for QRHC is 15.66 vs. an trade ratio of 19.40.
BioAtla, Inc. (BCAB)is reporting for the quarter ending December 31, 2022. The biomedical (gene) firm’s consensus earnings per share forecast from the three analysts that comply with the inventory is $-0.74. This worth represents a 17.46% lower in comparison with the identical quarter final yr. BCAB missed the consensus earnings per share within the 2nd calendar quarter of 2022 by -10%. Zacks Funding Analysis experiences that the 2022 Value to Earnings ratio for BCAB is -0.79 vs. an trade ratio of three.00.
Lument Finance Belief, Inc. (LFT)is reporting for the quarter ending December 31, 2022. The monetary companies firm’s consensus earnings per share forecast from the two analysts that comply with the inventory is $0.05. This worth represents a 54.55% lower in comparison with the identical quarter final yr. Zacks Funding Analysis experiences that the 2022 Value to Earnings ratio for LFT is 12.19 vs. an trade ratio of 12.40.
KULR Know-how Group, Inc. (KULR)is reporting for the quarter ending December 31, 2022. The consensus earnings per share forecast from the 1 analyst that follows the inventory is $-0.05. KULR reported earnings of $-0.04 per share for a similar quarter a yr in the past; representing a a improve of 25.00%.KULR missed the consensus earnings per share within the 2nd calendar quarter of 2022 by -25%. JOANN, Inc. (JOAN)is reporting for the quarter ending January 31, 2023. The retail firm’s consensus earnings per share forecast from the 1 analyst that follows the inventory is $0.33. This worth represents a 71.30% lower in comparison with the identical quarter final yr. The “days to cowl” for this inventory exceeds 17 days. Zacks Funding Analysis experiences that the 2023 Value to Earnings ratio for JOAN is -2.77 vs. an trade ratio of 10.00.
The views and opinions expressed herein are the views and opinions of the creator and don’t essentially mirror these of Nasdaq, Inc.
